anti obesity agents

Summary

Summary: Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.

Top Publications

  1. ncbi Drug treatments for obesity: orlistat, sibutramine, and rimonabant
    Raj S Padwal
    Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada
    Lancet 369:71-7. 2007
  2. ncbi A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity
    George A Bray
    Pennington Biomedical Research Center, Baton Rouge, Louisiana Baylor Hospital, Dallas, Texas, USA
    Obes Res 11:722-33. 2003
  3. ncbi Obesity
    Susan Z Yanovski
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 5450, USA
    N Engl J Med 346:591-602. 2002
  4. ncbi A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease
    Shira Zelber-Sagi
    The Liver Unit, Department of Gastroenterology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Clin Gastroenterol Hepatol 4:639-44. 2006
  5. ncbi Orlistat in the long-term treatment of obesity in primary care settings
    J Hauptman
    Department of International Clinical Research, Hoffman LaRoche Inc, Nutley, NJ 07110, USA
    Arch Fam Med 9:160-7. 2000
  6. doi Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats
    Andreas W Herling
    Therapeutic Department Metabolism, Pharmacology, H 821, Sanofi Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt Main, Germany
    Endocrinology 149:2557-66. 2008
  7. ncbi Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults
    S B Heymsfield
    Columbia University College of Physicians and Surgeons, St Luke s Roosevelt Hospital Center, New York, NY, USA
    Arch Intern Med 160:1321-6. 2000
  8. ncbi Ginseng berry reduces blood glucose and body weight in db/db mice
    J T Xie
    Tang Center for Herbal Medicine Research, Department of Anesthesia and Critical Care, Pritzker School of Medicine, University of Chicago, Illinois 60637, USA
    Phytomedicine 9:254-8. 2002
  9. ncbi Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
    Jean Pierre Despres
    Quebec Heart Institute, Laval Hospital Research Center, and the Division of Kinesiology, Department of Social and Preventive Medicine, Laval University, Ste Foy, Que, Canada
    N Engl J Med 353:2121-34. 2005
  10. ncbi Wild ginseng prevents the onset of high-fat diet induced hyperglycemia and obesity in ICR mice
    Se Na Yun
    Laboratory of Pharmacology and Clinical Pharmacy, School of Pharmacy, Kyung Hee University, Seoul 130 701, Korea
    Arch Pharm Res 27:790-6. 2004

Research Grants

  1. Post-DPP Follow-up-Study
    George Bray; Fiscal Year: 2007
  2. Hypothalamic SIRT1 and Energy Balance
    Eduardo A Nillni; Fiscal Year: 2010
  3. Aminosterol MSI-1436 as a Therapeutic for Obesity
    Michael McLane; Fiscal Year: 2004
  4. DIETARY FAT REGULATION OF HEPATIC GENE EXPRESSION
    DONALD JUMP; Fiscal Year: 1993
  5. Novel Puerarin Analogs with Anti-Diabetic Activity
    NICHOLAS CAIRNS; Fiscal Year: 2007
  6. Beta-adrenoceptor genetic polymorphisms and obesity
    Julie Johnson; Fiscal Year: 2002
  7. Genes mediating glucopenia-induced obesity in nematodes
    Charles Mobbs; Fiscal Year: 2007
  8. Oleylethanolamide derivatives as anti-obesity agents
    Daniele Piomelli; Fiscal Year: 2005
  9. Secreted Protein from Adipocytes and Preadipocytes
    CYDNEY BROOKS; Fiscal Year: 2002
  10. SPLIT-MAZE DISCOVERY OF ANTIOBESITY DRUGS
    Juan Ballesteros; Fiscal Year: 2003

Detail Information

Publications273 found, 100 shown here

  1. ncbi Drug treatments for obesity: orlistat, sibutramine, and rimonabant
    Raj S Padwal
    Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada
    Lancet 369:71-7. 2007
    ..Only then can patients and their physicians be confident that the putative benefits of such drugs outweigh their risks and costs...
  2. ncbi A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity
    George A Bray
    Pennington Biomedical Research Center, Baton Rouge, Louisiana Baylor Hospital, Dallas, Texas, USA
    Obes Res 11:722-33. 2003
    ..To evaluate the efficacy and safety of topiramate (TPM) for weight loss in healthy obese subjects...
  3. ncbi Obesity
    Susan Z Yanovski
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892 5450, USA
    N Engl J Med 346:591-602. 2002
  4. ncbi A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease
    Shira Zelber-Sagi
    The Liver Unit, Department of Gastroenterology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Clin Gastroenterol Hepatol 4:639-44. 2006
    ..Few controlled studies have addressed the issue of effective medical treatment for nonalcoholic fatty liver disease (NAFLD). We herein assessed the effect of orlistat in patients with NAFLD...
  5. ncbi Orlistat in the long-term treatment of obesity in primary care settings
    J Hauptman
    Department of International Clinical Research, Hoffman LaRoche Inc, Nutley, NJ 07110, USA
    Arch Fam Med 9:160-7. 2000
    ..To evaluate the long-term efficacy and tolerability within primary care settings of orlistat, a gastrointestinal lipase inhibitor, for the treatment of obesity...
  6. doi Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats
    Andreas W Herling
    Therapeutic Department Metabolism, Pharmacology, H 821, Sanofi Aventis Deutschland GmbH, Industriepark Hoechst, 65926 Frankfurt Main, Germany
    Endocrinology 149:2557-66. 2008
    ..When the amount of endogenous fat stores declined, rimonabant-induced increased energy expenditure was maintained by a re-increase in food intake...
  7. ncbi Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults
    S B Heymsfield
    Columbia University College of Physicians and Surgeons, St Luke s Roosevelt Hospital Center, New York, NY, USA
    Arch Intern Med 160:1321-6. 2000
    ..Orlistat is a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, promotes weight loss, and may reduce the risk of developing impaired glucose tolerance and type 2 diabetes in obese subjects...
  8. ncbi Ginseng berry reduces blood glucose and body weight in db/db mice
    J T Xie
    Tang Center for Herbal Medicine Research, Department of Anesthesia and Critical Care, Pritzker School of Medicine, University of Chicago, Illinois 60637, USA
    Phytomedicine 9:254-8. 2002
    ..01 compared to Day 0, respectively). The body weight of lean littermates also decreased at the same dose of extract. These data suggest that Panax ginseng berry extract may have therapeutic value in treating diabetic and obese patients...
  9. ncbi Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
    Jean Pierre Despres
    Quebec Heart Institute, Laval Hospital Research Center, and the Division of Kinesiology, Department of Social and Preventive Medicine, Laval University, Ste Foy, Que, Canada
    N Engl J Med 353:2121-34. 2005
    ..The Rimonabant in Obesity-Lipids (RIO-Lipids) study examined the effects of rimonabant on metabolic risk factors, including adiponectin levels, in high-risk patients who are overweight or obese and have dyslipidemia...
  10. ncbi Wild ginseng prevents the onset of high-fat diet induced hyperglycemia and obesity in ICR mice
    Se Na Yun
    Laboratory of Pharmacology and Clinical Pharmacy, School of Pharmacy, Kyung Hee University, Seoul 130 701, Korea
    Arch Pharm Res 27:790-6. 2004
    ..Taken together, WGEE has potential as a preventive agent for type 2 diabetes mellitus (and possibly obesity) and deserves clinical trial in the near future...
  11. ncbi Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
    Robin Christensen
    The Parker Institute, Musculoskeletal Statistics Unit, Frederiksberg Hospital, Frederiksberg, Denmark
    Lancet 370:1706-13. 2007
    ..We did a meta-analysis of all published randomised controlled trials to assess the efficacy and safety of the newly approved anti-obesity agent rimonabant...
  12. ncbi Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis
    Paul G Shekelle
    Southern California Evidence based Practice Center RAND, Santa Monica, Calif 90407 2138, USA
    JAMA 289:1537-45. 2003
    ..Ephedra and ephedrine sometimes are used for weight loss or enhanced athletic performance, but the efficacy and safety of these compounds are uncertain...
  13. ncbi Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials
    Brian Hutton
    Clinical Epidemiology Program, Ottawa Health Research Institute, Ottawa, Canada
    Am J Clin Nutr 80:1461-8. 2004
    ..Obesity is a growing health concern in Canada and the United States, and pharmacologic therapies such as orlistat are being more commonly prescribed to assist with weight loss...
  14. pmc The effect of Irvingia gabonensis seeds on body weight and blood lipids of obese subjects in Cameroon
    Judith L Ngondi
    Nutrition, HIV and Health Research Unit, Department of Biochemistry, P O Box 812, Faculty of Science, University of Yaounde I, Cameroon
    Lipids Health Dis 4:12. 2005
    ..On the other hand, the placebo group did not manifest any changes in blood lipid components. Irvingia gabonensis seed may find application in weight lose...
  15. ncbi Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus
    Andreas Maetzel
    University Health Network Research Institute, University of Toronto, Toronto, Ontario, Canada
    Pharmacoeconomics 21:501-12. 2003
    ..The perspective of the study was from the viewpoint of a US healthcare provider...
  16. ncbi Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women
    Maria Bougoulia
    Biochemistry Department, Aristoteles University Medical School, Thessaloniki, Greece
    Hormones (Athens) 5:259-69. 2006
    ....
  17. ncbi Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects
    Jianguo Zhi
    Department of Clinical Pharmacology, Hoffmann La Roche, Inc, Nutley, New Jersey 07110 1199, USA
    J Clin Pharmacol 42:1011-9. 2002
    ..In conclusion, except for cyclosporine, there was no effect of orlistat on the pharmacokinetics of selective concomitant medications when these drugs were taken concomitantly with orlistat...
  18. ncbi [Results from the observational study EPIGRAM: management of excess weight in general practice and follow-up of patients treated with orlistat]
    Muriel Vray
    Institut Pasteur, Bâtiment Laveran, Paris, France
    Therapie 60:17-24. 2005
    ..The treatment cost was the main reason for definitive treatment discontinuation for more than 50% of the patients. The average weight loss was 5% and 9% after 3 and 12 months of treatment, respectively...
  19. ncbi The corticotropin-releasing factor system as a potential target for antiobesity drugs
    Christian Doyon
    Département d anatomie et de physiologie, Universite Laval, Quebec, Canada
    Drug News Perspect 17:505-17. 2004
    ..Based on recent progress, we conclude that the CRF(2) receptor could be a potential target for the development of an antiobesity drug...
  20. ncbi Orlistat for the treatment of obesity: cost utility model
    D R Foxcroft
    School of Health and Social Care, Oxford Brookes University, Oxford, UK
    Obes Rev 6:323-8. 2005
    ..The EMEA criteria should be considered in any future changes to the NICE guidance or in guidance issued by similar agencies...
  21. ncbi Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland
    L A Lacey
    Lacey Solutions Ltd, Dublin, Ireland
    Int J Obes (Lond) 29:975-82. 2005
    ..To assess the cost-effectiveness of orlistat plus a calorie-controlled diet compared with a calorie-controlled diet alone for the treatment of overweight and obese patients in Ireland...
  22. pmc Long term pharmacotherapy for obesity and overweight: updated meta-analysis
    Diana Rucker
    Department of Medicine, University of Alberta, Edmonton, AB, Canada
    BMJ 335:1194-9. 2007
    ..To summarise the long term efficacy of anti-obesity drugs in reducing weight and improving health status...
  23. ncbi Common dietary supplements for weight loss
    Robert B Saper
    Harvard Medical School, Boston, Massachusetts, USA
    Am Fam Physician 70:1731-8. 2004
    ..John's wort in weight loss, physicians should caution patients about the use of these supplements and closely monitor those who choose to use these products...
  24. ncbi Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects
    Michiko Itoh
    Department of Molecular Medicine and Metabolism, Medical Research Institute, Tokyo Medical and Dental University, 2 3 10 Kanda surugadai, Chiyoda ku, Tokyo 101 0062, Japan
    Arterioscler Thromb Vasc Biol 27:1918-25. 2007
    ..Here we investigated the effect of highly purified eicosapentaenoic acid (EPA) on production of adiponectin, the only established antiatherogenic and antiinflammatory adipocytokine, in rodent models of obesity and human obese subjects...
  25. ncbi Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group
    S Rossner
    Obesity Unit, Huddinge Hospital, Stockholm, Sweden
    Obes Res 8:49-61. 2000
    ....
  26. ncbi Anti-obesity effect of dietary diacylglycerol in C57BL/6J mice: dietary diacylglycerol stimulates intestinal lipid metabolism
    Takatoshi Murase
    Biological Science Laboratories, Kao Corporation, 2606 Akabane, Ichikai machi, Haga gun, Tochigi 321 3497, Japan
    J Lipid Res 43:1312-9. 2002
    ..Thus, dietary DG reduces body weight gain that accompanies the stimulation of intestinal lipid metabolism, and these effects may be related to the characteristic metabolism of DG in the small intestine...
  27. doi Comparison of the antiobesity effects of the protopanaxadiol- and protopanaxatriol-type saponins of red ginseng
    Ji Hyun Kim
    Research Institute of Immunobiology, The Catholic University of Korea, Seoul 137 701, Korea
    Phytother Res 23:78-85. 2009
    ..The results suggest that the antiobesity activity of PD and PT type saponins may result from inhibiting energy gain, normalizing hypothalamic neuropeptides and serum biochemicals related to the control of obesity...
  28. ncbi The ORLIstat and CArdiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study
    T P Didangelos
    Diabetes Center, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece
    Curr Med Res Opin 20:1393-401. 2004
    ..Metabolic syndrome (MetSyn) is associated with a marked increase in the risk of cardiovascular disease, especially in patients with type 2 diabetes mellitus (DM)...
  29. ncbi Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines
    G Valsamakis
    Department of Diabetes and Endocrinology, Birmingham Heartlands Hospital, Birmingham, UK
    Metabolism 53:430-4. 2004
    ..Modest weight loss is also associated with potentially favourably changes in serum adipocytokines, particularly in a rise of serum adiponectin. Reduction of waist circumference is associated with a change in serum resistin...
  30. ncbi Pharmacotherapy for obesity
    Jason C G Halford
    Kissileff Laboratory for the Study of Human Ingestive Behaviour, School of Psychology, University of Liverpool, Eleanor Rathbone Building, Bedford Street South, Liverpool L69 7ZA, UK
    Appetite 46:6-10. 2006
    ..Despite this, in the XENDOS trial, the modest placebo-subtract weight loss produced by orlistat (2.8 kg) reduced the incidence of diabetes by over a third. Recent data on the potential anti-obesity drug rimonabant are also reviewed...
  31. ncbi Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21
    Francisco Javier Pavon
    Fundacion IMABIS, Neuropharmacology, Hospital Carlos Haya, Avenida Carlos Haya 82, 7 a planta, Pabellon A, Malaga 29010, Spain
    Neuropharmacology 51:358-66. 2006
    ....
  32. ncbi Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice
    J D Douketis
    Department of Medicine, McMaster University, Hamilton, Canada
    Int J Obes (Lond) 29:1153-67. 2005
    ....
  33. pmc Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats
    Angels Fisas
    Laboratorios Dr Esteve S A, Av Mare de Déu de Montserrat 221, 08041 Barcelona, Spain
    Br J Pharmacol 148:973-83. 2006
    ..These results show that the 5-HT(6) receptor partial agonist, E-6837, is a promising new approach to the management of obesity with the potential to produce greater sustained weight loss than sibutramine...
  34. ncbi Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial
    Jean Pierre Chanoine
    Endocrinology and Diabetes Unit, British Columbia Children s Hospital, Vancouver, Canada
    JAMA 293:2873-83. 2005
    ..In this population, behavioral therapy alone has had limited success in providing meaningful, sustained weight reduction, and pharmacological treatment has not been extensively studied...
  35. ncbi Orlistat for obesity: benefits beyond weight loss
    Ching Jung Hsieh
    Division of Edocrinology and Metabolosm, Department of Internal Medicine, Chang Gung Memorial Hospital, 123 Ta Pei Road, Niao Sung Hsiang, Kaohsiung Hsien 83305, Taiwan
    Diabetes Res Clin Pract 67:78-83. 2005
    ..Therefore, orlistat appears to have anti-diabetic and anti-atherogenic properties and may help prevent metabolic syndrome in the overweight people...
  36. ncbi Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors
    L Samuelsson
    Department of Vascular Diseases, University Hospital, S 205 02 Malmo, Sweden
    Diabetes Obes Metab 5:195-201. 2003
    ....
  37. ncbi Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients
    A Halpern
    Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo, Brazil
    Diabetes Obes Metab 5:180-8. 2003
    ..i.d.) plus similar instructions. The secondary objectives were to evaluate the effects on glucose profile and to determine the tolerability and safety of orlistat...
  38. doi Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study
    Erik L Madsen
    Department of Endocrinology and Metabolism C, Aarhus University Hospital, Aarhus Sygehus, Tage Hansensgade 2, DK 8000 Aarhus C, Denmark
    Eur J Endocrinol 158:179-87. 2008
    ..Moreover, to evaluate the effect of the lipase inhibitor, orlistat, on these parameters...
  39. ncbi Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Harold Bays
    L MARC Research Center, Medical Director President, 3288 Illinois Avenue, Louisville, KY 40213, USA
    Expert Rev Cardiovasc Ther 4:871-95. 2006
    ..This review describes how adiposopathy interventions may affect fat function, and thus improve EFRMD...
  40. ncbi Metformin: new understandings, new uses
    Ripudaman S Hundal
    Diabetes and Metabolic Disease Center, Christiana Care, Wilmington, Delaware, USA
    Drugs 63:1879-94. 2003
    ..We also discuss its potential role for a variety of insulin resistant and prediabetic states, including impaired glucose tolerance, obesity, polycystic ovary syndrome and the metabolic abnormalities associated with HIV disease...
  41. ncbi Diabesity: are weight loss medications effective?
    Alfredo Halpern
    Medical School, University of Sao Paulo, Sao Paulo, Brazil
    Treat Endocrinol 4:65-74. 2005
    ..These trials show variable benefits in terms of effects on glucose profiles...
  42. ncbi The effect of orlistat-induced weight loss on interleukin-6 and C-reactive protein levels in obese subjects
    Dilek Yesilbursa
    Cardiology Department, Uludag University Medical School, Bursa, Turkey
    Acta Cardiol 60:265-9. 2005
    ..The aim of this study is to investigate changes in the inflammatory markers interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hs-CRP) during weight reduction with orlistat treatment in obese patients...
  43. ncbi Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians
    Vincenza Snow
    American College of Physicians, Philadelphia, Pennsylvania 19106, USA
    Ann Intern Med 142:525-31. 2005
    ..This guideline is not intended to be used by commercial weight loss centers or for direct-to-consumer marketing by manufacturers and does not apply to patients with body mass indices below 30 kg/m2...
  44. ncbi Effect of short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults
    Robert D Brook
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Am J Cardiol 93:1012-6. 2004
    ..18 +/- 5.89 vs 18.87 +/- 7.11%, p = 0.13) of the brachial artery. A moderate degree of weight reduction over 3 months improved the metabolic syndrome profile but not the vascular dysfunction associated with uncomplicated obesity...
  45. ncbi Rats treated with oleoyl-oestrone maintain glucidic homeostasis: comparisons with a pair-fed model
    Anna Salas
    Department de Nutrició i Bromatologia, Facultat de Biologia, Universitat de Barcelona, Av Diagonal, 645, 08028 Barcelona, Spain
    Br J Nutr 94:738-45. 2005
    ....
  46. ncbi Effect of orlistat on cardiovascular disease risk in obese adults
    B A Swinburn
    Department of Community Health, University of Auckland, Auckland, New Zealand
    Diabetes Obes Metab 7:254-62. 2005
    ..placebo on the predicted 10-year cardiovascular disease (CVD) risk in obese people with one or more cardiovascular risk factors treated for 12 months, in conjunction with a fat-reduced, but otherwise ad libitum, diet...
  47. ncbi Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients
    Taner Damci
    Istanbul University Cerrahpasa Medical School, Department of Internal Medicine, Division of Endocrinology Diabetes and Metabolism, Istanbul, Turkey
    Diabetes Care 27:1077-80. 2004
    ..In this pilot study, we tested the hypothesis that increased levels of these intestinal hormones may be involved in the improvement of postprandial hyperglycemia observed previously with orlistat in type 2 diabetic patients...
  48. ncbi The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen
    Sergio Britto Garcia
    Department of Pathology, Ribeirao Preto Medical School, University of Sao Paulo, USP, Avenida Bandeirantes 3900, 14049 900 Ribeirao Preto, SP, Brazil
    Cancer Lett 240:221-4. 2006
    ..After 30 days, Orlistat was associated to a significant increase in the number of colonic ACFs and cell proliferation in DMH-treated animals, independently of the HFD...
  49. ncbi Anti-obesity effect of Nelumbo nucifera leaves extract in mice and rats
    Yuka Ono
    Matsuura Yakugyo Co Ltd, Enjo cho, Showa Ku, Nagoya 459 8001, Japan
    J Ethnopharmacol 106:238-44. 2006
    ..Therefore, NNE impaired digestion, inhibited absorption of lipids and carbohydrates, accelerated lipid metabolism and up-regulated energy expenditure. Consequently, NNE is beneficial for the suppression of obesity...
  50. ncbi Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents
    David Maahs
    Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Endocr Pract 12:18-28. 2006
    ..To evaluate the efficacy of orlistat to enhance weight loss in obese adolescents...
  51. ncbi Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes
    Y J Hung
    Division of Endocrinology and Metabolism, Tri Service General Hospital, National Defense Medical Center, Taipei, Taiwan
    Diabet Med 22:1024-30. 2005
    ..To evaluate the effect of sibutramine on weight loss, insulin sensitivity and serum adiponectin levels in obese patients with Type 2 diabetes...
  52. pmc The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome
    Julius Oben
    Department of Biochemistry, University of Yaounde I, Yaounde, Cameroon
    Lipids Health Dis 5:24. 2006
    ..The purpose of the present study was to investigate the use of a Cissus quadrangularis formulation in the management of metabolic syndrome, particularly weight loss and central obesity...
  53. ncbi Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity
    Linus S Lin
    Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA
    J Med Chem 49:7584-7. 2006
    ..These efforts led to the identification of compound 48 for development as a clinical candidate for the treatment of obesity...
  54. ncbi The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study
    F Lindgarde
    Department of Vascular Disease, Malmo University Hospital, University of Lund, 20502 Malmo, Sweden
    J Intern Med 248:245-54. 2000
    ..To assess the effect of orlistat on body weight and cardiovascular risk amongst obese patients at high coronary risk...
  55. doi Surgical treatment of obesity
    Mariëlle J F Bult
    Department of Internal Medicine, Diakonessenhuis Utrecht, Bosboomstraat 1, 3582 KE Utrecht, The Netherlands
    Eur J Endocrinol 158:135-45. 2008
    ..Proposed criteria for bariatric surgery are given. Also, some attention is devoted to more basic insights that bariatric surgery has provided. Finally we deal with unsolved questions and future directions for research...
  56. ncbi Use of prescription weight loss pills among U.S. adults in 1996-1998
    L K Khan
    Division of Nutrition and Physical Activity, Centers for Disease Control and Prevention, 4770 Buford Highway, NE, Mailstop K26, Atlanta, GA 30341, USA
    Ann Intern Med 134:282-6. 2001
    ..Pharmacotherapy is recommended for the treatment of obese persons with a body mass index of 30 kg/m(2) or higher or a body mass index of at least 27 kg/m(2) plus an obesity-related comorbid condition...
  57. ncbi Pharmacological treatment of the overweight patient
    George A Bray
    Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA 70808, USA
    Pharmacol Rev 59:151-84. 2007
  58. ncbi Orlistat: selective inhibition of caloric absorption can affect long-term body weight
    J Hauptman
    Hoffmann La Roche Inc, Nutley, NJ 07110 1199, USA
    Endocrine 13:201-6. 2000
    ..Orlistat acts locally in the gastrointestinal tract and is only minimally absorbed. In long-term clinical trials, orlistat was well tolerated by both diabetic and nondiabetic subjects...
  59. ncbi Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial
    F Xavier Pi-Sunyer
    Obesity Research Center, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY 10025, USA
    JAMA 295:761-75. 2006
    ..Rimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight and improve cardiometabolic risk factors in patients who are overweight or obese...
  60. ncbi Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial
    David E Kelley
    Montifiore Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Diabetes Care 25:1033-41. 2002
    ..The aim of this study was to assess the effect of orlistat, a gastrointestinal lipase inhibitor, on weight loss, glycemic control, and cardiovascular risk factors in overweight or obese insulin-treated type 2 diabetic patients...
  61. ncbi Daily oral oleoyl-estrone gavage induces a dose-dependent loss of fat in Wistar rats
    M del Mar Grasa
    , Universitat de Barcelona, Spain
    Obes Res 9:202-9. 2001
    ..These results agree with the postulated role of oleoyl-estrone as a ponderostat signal...
  62. ncbi Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers
    F Carriere
    Laboratoire de Lipolyse Enzymatique, Centre National de la Recherche Scientifique, Institut de Biologie Structurale et Microbiologie, F 13402 Marseille Cedex 20, France
    Am J Physiol Gastrointest Liver Physiol 281:G16-28. 2001
    ..As predicted from the previous results, the effects of Orlistat on fat excretion levels were found to be much greater with the solid (40.5--57.4% of ingested fat) than with the liquid (4.2--18.8%) test meal...
  63. ncbi The administration of oleoyl-estrone to lactating dams induces selective changes in the normal growth pattern of their pups
    B García-Peláez
    Departament de Nutrició i Bromatologia, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain
    Horm Metab Res 39:582-8. 2007
    ..Thus, treatment affects dams in a selective way that does not coincide with a simple food restriction model...
  64. ncbi Influence of orlistat on bone turnover and body composition
    A Gotfredsen
    Department of Endocrinology, Hvidovre University Hospital, Denmark
    Int J Obes Relat Metab Disord 25:1154-60. 2001
    ..To investigate the influence of the pancreas lipase inhibitor orlistat (OLS) on calcium metabolism, bone turnover, bone mass, bone density and body composition when given for obesity as adjuvant to an energy- and fat-restricted diet...
  65. ncbi Oleoyl-estrone does not have direct estrogenic effects on rats
    C Cabot
    , Facultat de Biologia, Universitat de Barcelona, Spain
    Life Sci 69:749-61. 2001
    ..The oral administration of OE as a slimming drug, then, do not result in estrogenic side effects over a wide range of daily doses...
  66. ncbi Orlistat inhibits dietary cholesterol absorption
    B Mittendorfer
    Department of Internal Medicine and Center for Human Nutrition, Washington University School of Medicine, St. Louis, Missouri 63110, USA
    Obes Res 9:599-604. 2001
    ..01). DISCUSSION: These data demonstrate that orlistat inhibits dietary cholesterol absorption, which may have beneficial effects on lipoprotein metabolism in obese subjects that are independent of weight loss itself...
  67. ncbi Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents
    Tung M Fong
    Department of Metabolic Disorders, Merck Research Laboratories, R80M 213, P O Box 2000, Rahway, NJ 07065, USA
    J Pharmacol Exp Ther 321:1013-22. 2007
    ..These studies demonstrated that MK-0364 is a highly potent and selective CB1R inverse agonist and that it is orally active in rodent models of obesity...
  68. ncbi [Pharmacological therapy of obesity]
    Uberto Pagotto
    UO di Endocrinologia e Centro di Ricerca Biomedica Applicata CRBA, Dipartimento di Medicina Interna e Gastroenterologia, Policlinico S Orsola Malpighi, Università Alma Mater Studiorum, Bologna
    G Ital Cardiol (Rome) 9:83S-93S. 2008
    ..9 kg/m2 with major obesity-related comorbidities such as hypertension, diabetes, dyslipidemia, obstructive sleep apnea, and metabolic syndrome...
  69. ncbi [Impact of weight loss on adipocytokines, C-reactive protein and insulin sensitivity in hypertensive women with central obesity]
    Rodolfo Leão Borges
    Universidade Federal de Sao Paulo, UNIFESP Universidade de Brasília UnB São Paulo, SP Brasília, DF Brazil
    Arq Bras Cardiol 89:409-14. 2007
    ..To assess the impact of weight reduction on serum adipocytokines, C-reactive protein (CRP), and insulin sensitivity in hypertensive female patients with central obesity...
  70. doi Potential risks associated with the use of herbal anti-obesity products
    Thomas Y K Chan
    Centre for Food and Drug Safety, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
    Drug Saf 32:453-6. 2009
    ..They should warn their patients about the heterogeneous nature of these agents and the potential risks associated with their use. They should report suspected adverse reactions to their national spontaneous reporting system...
  71. ncbi Clinical outcome of adjunctive topiramate treatment in a sample of refractory bipolar patients with comorbid conditions
    Constance Guille
    Harvard Bipolar Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    Prog Neuropsychopharmacol Biol Psychiatry 26:1035-9. 2002
    ..7 lb while on topiramate. Topiramate appears to be a promising agent for the treatment of bipolar disorder associated with comorbid psychiatric conditions and obesity...
  72. ncbi The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes
    Peter C Y Tong
    Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
    Arch Intern Med 162:2428-35. 2002
    ..We examined the weight-losing effect of orlistat treatment on insulin sensitivity and cardiovascular risk factors in a group of severely obese young Chinese patients with or without type 2 diabetes mellitus...
  73. ncbi Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus
    K C B Tan
    Department of Medicine, University of Hong Kong and Clinical Biochemistry Unit, Queen Mary Hospital, Hong Kong
    Diabet Med 19:944-8. 2002
    ..We postulate that orlistat, a gastrointestinal lipase inhibitor, may cause changes in post-prandial lipoprotein metabolism by reducing dietary triglyceride absorption...
  74. pmc The effect of Cissus quadrangularis (CQR-300) and a Cissus formulation (CORE) on obesity and obesity-induced oxidative stress
    Julius E Oben
    Laboratory of Nutrition and Nutritional Biochemistry, Department of Biochemistry, University of Yaounde I, Yaounde, Cameroon
    Lipids Health Dis 6:4. 2007
    ....
  75. ncbi New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat
    A J Scheen
    Division of Diabetes, Nutrition and Metabolic Disorders, Division of Clinical Pharmacology and Therapeutics, Department of Medicine, CHU Sart Tilman, Liege, Belgium
    Diabetes Metab 28:437-45. 2002
    ....
  76. ncbi Success rate of Orlistat in primary-care practice is limited by failure to follow prescribing recommendations: the referral letter content vs clinical reality
    Y Linné
    Int J Obes Relat Metab Disord 27:1434-5. 2003
    ..A simple questionnaire to 70 such patients, however, revealed that in many cases the referral physician had not observed basic rules and regulations, nor given appropriate information on Orlistat use...
  77. ncbi Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study
    Bjørn Richelsen
    Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus, Denmark
    Diabetes Care 30:27-32. 2007
    ....
  78. pmc Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications
    Soren Snitker
    University of Maryland School of Medicine, Baltimore, MD 21209, USA
    Am J Clin Nutr 89:45-50. 2009
    ..Capsinoids from the Capsicum genus of plants are nonpungent capsaicin-related substances with effects on metabolism and body weight in animals...
  79. ncbi Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance
    A Gursoy
    Department of Endocrinology and Metabolic Diseases, Ankara University School of Medicine, Ankara, Turkey
    Eat Weight Disord 11:e127-32. 2006
    ..05 vs. last visit for both groups, p>0.05 between groups). Both drugs in an obesity management program can achieve substantial weight loss. However, noncompliance and rebound weight regain after noncompliance are considerable problems...
  80. ncbi [Struggle about the best reducing diet, Fat gone by means of more fat?]
    Angelika Bischoff
    MMW Fortschr Med 146:4-6. 2004
  81. ncbi A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin
    C Berne
    Department of Medicine, University Hospital, Uppsala, Sweden
    Diabet Med 22:612-8. 2005
    ..To assess the effects of orlistat vs. placebo, in combination with a weight management programme, on weight loss and metabolic control in obese patients with Type 2 diabetes...
  82. ncbi Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients
    Kuei Mei Chou
    Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Chang Gung University College of Medicine, Taoyuan, Taiwan
    Chang Gung Med J 30:538-46. 2007
    ..We assessed and directly compared weight loss effects of sibutramine and orlistat treatment in a group of obese, poorly-controlled type 2 diabetic patients...
  83. ncbi Managing type 2 diabetes mellitus in patients with obesity
    Hans Hauner
    German Diabetes Research Institute, Heinrich Heine University Dusseldorf, Dusseldorf, Germany
    Treat Endocrinol 3:223-32. 2004
    ....
  84. ncbi [Obesity in adults]
    P M Suter
    Medizinische Poliklinik, Universitatsspital Zurich
    Praxis (Bern 1994) 96:1617-24; quiz 1625-6. 2007
  85. ncbi Effect of weight loss on P wave dispersion in obese subjects
    Mehmet Duru
    Department of Emergency Medicine, School of Medicine, Mustafa Kemal University, 31100 Antakya, Hatay, Turkey
    Obesity (Silver Spring) 14:1378-82. 2006
    ..The aim of this study was to investigate effect of loss weight on P wave dispersion in obese subjects...
  86. ncbi Long-term pharmacotherapy for obesity
    Samuel Klein
    Division of Geriatrics and Nutritional Sciences, Center for Human Nutrition, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8031, St Louis, MO 63110, USA
    Obes Res 12:163S-6S. 2004
    ..Their use must be combined with behavior modification and a structured meal plan, however, for patients to reap the full benefits of such treatment...
  87. ncbi Current and novel approaches to the drug therapy of obesity
    Jean Philippe Chaput
    Division of Kinesiology, Department of Social and Preventive Medicine, Faculty of Medicine, Laval University, Ste Foy, Quebec, G1K 7P4, Canada
    Eur J Clin Pharmacol 62:793-803. 2006
    ..Obesity has been described as the greatest current threat to human health. Although diet and lifestyle changes remain the cornerstones of therapy for obesity, weight losses are often small, and long-term success is disappointing...
  88. ncbi Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial
    Paul E O'Brien
    Centre for Obesity Research and Education, Monash University Medical School, The Alfred Hospital, Melbourne, Victoria, Australia
    Ann Intern Med 144:625-33. 2006
    ..Obesity is a major, growing health problem. Observational studies suggest that bariatric surgery is more effective than nonsurgical therapy, but no randomized, controlled trials have confirmed this...
  89. ncbi Therapeutic options for modifying cardiometabolic risk factors
    Louis J Aronne
    Weill Medical College of Cornell University, Columbia College of Physicians and Surgeons, and the Comprehensive Weight Control Program, New York Presbyterian Hospital, New York, New York 10021, USA
    Am J Med 120:S26-34. 2007
    ....
  90. ncbi Influence of weight loss on myocardial performance index
    Sennur Unal Dayi
    Department of Cardiology, Siyami Ersek Cardiothoracic Surgery Center, Istanbul, Turkey
    Heart Vessels 21:84-8. 2006
    ..13 to 0.50 +/- 0.13 (P = 0.0001). Weight loss ameliorates MPI and seems to be a clinically relevant measurement of left ventricular global function, and may prove to be a valuable tool in assessing the risk of developing heart failure...
  91. ncbi The effects of orlistat treatment interruption on weight and associated metabolic parameters
    K Owen
    Third Medical Department of the First Faculty of Medicine, Charles University in Prague, General Teaching Hospital, Czech Republic
    Prague Med Rep 107:394-400. 2006
    ....
  92. ncbi Combining behavioral and pharmacological treatments for obesity
    Suzanne Phelan
    University of Pennsylvania School of Medicine, Philadelphia, USA
    Obes Res 10:560-74. 2002
    ..The article examines possible methods of sequencing behavioral and pharmacological therapies and offers suggestions for future research...
  93. ncbi The influence of a 3-month weight reduction therapy with Orlistat on serum vitamin B12 and folic acid concentration in obese women
    M Holecki
    1Department of Pathophysiology, Medical University of Silesia, Katowice, Poland
    Int J Obes (Lond) 30:1017-8. 2006
    ..Serum folic acid, but not the vitamin B(12) concentration, was found to be significantly lower in obese subjects than in the control ones...
  94. ncbi Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes
    Y F Shi
    Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China
    Diabet Med 22:1737-43. 2005
    ....
  95. ncbi The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss
    Rachel Rowe
    Wythenshawe Hospital, Manchester, UK
    Curr Med Res Opin 21:1885-90. 2005
    ..The purpose of this study was to characterise concomitant diabetes drug use and the related costs in patients with diabetes treated with orlistat (Xenical) in the first 6 months of treatment...
  96. ncbi Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study
    D N Kiortsis
    Laboratory of Physiology, Medical School, University of Ioannina, Panepistimiou Avenue, 45110 Ioannina, Greece
    Nutr Metab Cardiovasc Dis 18:207-10. 2008
    ..Moreover, no study has evaluated the effects of orlistat treatment on mood. The purpose of our study was to assess the effects of sibutramine and orlistat on mood in obese and overweight subjects...
  97. ncbi Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success
    K Elfhag
    Obesity Unit, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
    Diabetes Obes Metab 10:498-505. 2008
    ..To study the associations between weight loss with sibutramine and orlistat with psychological aspects that may interact with patients' response to these drugs...
  98. ncbi X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance
    H Toplak
    Department of Medicine, Medical University, Graz, Austria
    Diabetes Obes Metab 7:699-708. 2005
    ..To determine the effect of two different levels of energy deficit on weight loss in obese patients treated with orlistat...
  99. ncbi [Pharmacotherapy for weight loss in patients with type 2 diabetes]
    Søren Toubro
    Københavns Universitet, Det Biovidenskabelige Fakultet for Fødevarer, Veterinaermedicin og Naturressourcer, Institut for Human Ernaering, og Hvidovre Hospital, Ernaeringskonsulenterne Afdeling 225
    Ugeskr Laeger 169:2619-22. 2007
  100. ncbi Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up
    Marion J Franz
    Nutrition Concepts by Franz, Inc, Minneapolis, MN 55439, USA
    J Am Diet Assoc 107:1755-67. 2007
    ....
  101. ncbi Incorrect use of orlistat and sibutramine in clinical practice
    Anna Dahlin
    Medical Products Agency, P O Box 26, 751 03 Uppsala, Sweden
    Eur J Clin Pharmacol 63:205-9. 2007
    ..To investigate how the antiobesity drugs orlistat and sibutramin are prescribed in relation to the approved indications and the Swedish subsidiary rules...

Research Grants111 found, 100 shown here

  1. Post-DPP Follow-up-Study
    George Bray; Fiscal Year: 2007
    ..women, and in older subjects in the DPP. The current application is for 5 years of funding, although the some of the goals of the projects described will require a 10-year study. ..
  2. Hypothalamic SIRT1 and Energy Balance
    Eduardo A Nillni; Fiscal Year: 2010
    ..Therefore, this proposal provides a novel view assigned to Sirt1 as a cellular energy sensor regulating energy balance at the hypothalamic level. ..
  3. Aminosterol MSI-1436 as a Therapeutic for Obesity
    Michael McLane; Fiscal Year: 2004
    ..abstract_text> ..
  4. DIETARY FAT REGULATION OF HEPATIC GENE EXPRESSION
    DONALD JUMP; Fiscal Year: 1993
    ..Finally, it is not unreasonable to expect that the PUFA mechanism of gene control may extend beyond lipogenesis and could explain other metabolic actions of PUFA...
  5. Novel Puerarin Analogs with Anti-Diabetic Activity
    NICHOLAS CAIRNS; Fiscal Year: 2007
    ..It is anticipated that these studies will lead to the development of a new class of novel antidiabetic and antiobesity agents based on the puerarin structure. ..
  6. Beta-adrenoceptor genetic polymorphisms and obesity
    Julie Johnson; Fiscal Year: 2002
    ..Additionally, genotyping individuals early in age may help to identify those at increased risk of obesity prior to them becoming obese so that they may take appropriate preventive measures. ..
  7. Genes mediating glucopenia-induced obesity in nematodes
    Charles Mobbs; Fiscal Year: 2007
    ..Of particular interest will be genes whose ablation does not produce an obvious phenotype in standard conditions, but whose ablation blocks glucopenia-induced obesity. These studies will suggest potential targets for anti-obesity drugs ..
  8. Oleylethanolamide derivatives as anti-obesity agents
    Daniele Piomelli; Fiscal Year: 2005
    ....
  9. Secreted Protein from Adipocytes and Preadipocytes
    CYDNEY BROOKS; Fiscal Year: 2002
    ..This work will therefore produce commercially viable targets, assays, and eventual lead compounds for development into anti-obesity drugs. ..
  10. SPLIT-MAZE DISCOVERY OF ANTIOBESITY DRUGS
    Juan Ballesteros; Fiscal Year: 2003
    ..This new approach has the potential to develop higher quality leads, faster and cheaper than the current state of art. ..
  11. Novel THC/Anandamide Hybrids as Appetite Suppressants
    ANURADHA MAHADEVAN; Fiscal Year: 2006
    ..The long-term objective of this proposal is to develop a novel anti-obesity drug that is both safe and effective. ..
  12. GENETIC ANALYSIS OF B3 ADRENERGIC RECEPTOR FUNCTION
    BRADFORD LOWELL; Fiscal Year: 2002
    ....
  13. DIETARY OBESITY
    George Bray; Fiscal Year: 2007
    ..We now propose these well founded, important and exciting studies which will provide critical new insights into anatomical, physiological and molecular mechanisms by which high levels of dietary fat induce obesity. ..
  14. Health Outcomes of Weight loss: Look AHEAD -Action for Health in Diabetes
    George Bray; Fiscal Year: 2007
    ..These procedures will enable us to analyze the effects of the intervention on serious cardiovascular- related factors and complications, and cost-effectiveness of the intervention. ..
  15. Zonisamide for Weight Reduction in Obese Adults
    Kishore Gadde; Fiscal Year: 2009
    ..We will also systematically assess whether weight loss achieved with zonisamide treatment can reduce metabolic and cardiovascular risk factors. ..
  16. OBESITY RESEARCH CENTER TRAINING PROGRAM
    F Pi Sunyer; Fiscal Year: 2007
    ..The program is intended to develop independent investigative skills and a rigorous approach to investigation through regular research and didactic seminars. A broad program of courses is available to the trainees at Columbia University. ..
  17. Diabetes Prevention Program Long-Term Follow-up Study
    F Pi Sunyer; Fiscal Year: 2007
    ..women, and in older subjects in the DPP. The current application is for 5 years of funding, although the some of the goals of the projects described will require a 10-year study. ..
  18. Look AHEAD: Action for Health Diabetes
    F Pi Sunyer; Fiscal Year: 2007
    ..These procedures will enable us to analyze the effects of the intervention on serious cardiovascular- related factors and complications, and cost-effectiveness of the intervention. ..
  19. Heavy Metal and Drug Self-Administration: Mechanisms
    Paul Wellman; Fiscal Year: 2009
    ..e., lead contamination and cocaine use. Based on the available literature, there is reason to believe that environmental pollutants may increase vulnerability to drug addiction. ..
  20. Psychostimulants and Alpha-1 Adrenoceptor Subtypes
    Paul Wellman; Fiscal Year: 2006
    ..These studies will advance our understanding of the behavioral functions of brain a l-AR subtypes and may lead to the identification of new drugs that inhibit eating without activating brain reinforcement systems. ..
  21. WEIGHT CONNECTION: WEIGHT LOSS MAINTANANCE USING THE WEB
    Lee Kaplan; Fiscal Year: 2001
    ..abstract_text> ..
  22. THE ROLE OF PLACENTAL LACTOGEN IN FETAL DEVELOPMENT
    Michael Freemark; Fiscal Year: 1990
    ....
  23. LIFESTYLE ACTIVITY FOR WEIGHT MANAGEMENT
    Thomas Wadden; Fiscal Year: 2003
    ..The predicted superiority of lifestyle activity is based on extensive pilot data and, if confirmed, should significantly improve the management of obesity and its associated health complications. ..
  24. Mid-Career Investigator Award in Eating and Weight
    Carlos Grilo; Fiscal Year: 2007
    ..Dr. has recruited strong postdoctoral fellows and is well positioned to mentor them and faculty. Funded programs provide unique resources for training the next generation of clinical-researchers of eating/weight disorders ..
  25. THE ROLE OF PLACENTAL LACTOGEN IN FETAL DEVELOPMENT
    Michael Freemark; Fiscal Year: 2007
    ..The results of our studies should provide new insist into the roles of pituitary and placental hormones in adipose development and function. ..
  26. THYROID HORMONE RECEPTOR
    John Baxter; Fiscal Year: 1999
    ..The results should be applicable to the function of ligands that act through the nuclear receptor superfamily in general. ..
  27. Pharmacogenomics of Gastric Function & Weight in Obesity
    MICHAEL L CAMILLERI; Fiscal Year: 2010
    ....
  28. Metabolic and Epigenetic Effects of Maternal High Fat Diet in Obesity Prone Rats
    Timothy H Moran; Fiscal Year: 2010
    ..The results of these experiments will enhance our understanding of the etiology of obesity and metabolic disease ultimately allowing the development of rational clinical interventions for such conditions. ..
  29. MENOPAUSE EFFECT ON OBESITY, ENERGY BALANCE AND INSULIN
    Steven Smith; Fiscal Year: 2006
    ..abstract_text> ..
  30. Postoperative dietary counseling after bariatric surgery
    DAVID SARWER; Fiscal Year: 2005
    ..Results of this study could have a significant impact on the postoperative care of these individuals. ..
  31. THYROID HORMONE RECEPTOR
    John Baxter; Fiscal Year: 1991
  32. Breast and Cervical Cancer Screening in Obese Women
    Jeanne Ferrante; Fiscal Year: 2007
    ..abstract_text> ..
  33. GASTROINTESTINAL INTEGRATION AND FEEDING
    Timothy Moran; Fiscal Year: 2004
    ....
  34. Mechanisms Defending Fat Mass in Human after Lipectomy
    Robert Eckel; Fiscal Year: 2007
    ..abstract_text> ..